𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients

✍ Scribed by Karsten Wursthorn; Mechthild Jung; Antonio Riva; Zachary D. Goodman; Patricia Lopez; Weibin Bao; Michael P. Manns; Heiner Wedemeyer; Nikolai V. Naoumov

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
565 KB
Volume
52
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of sustained response to pegi
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Characterization of viral kinetics in pa
Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B
✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Entecavir treatment for up to 5 years in
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B
✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB 👁 2 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E

The absence of hepatitis B virus DNA in
The absence of hepatitis B virus DNA in hepatitis B e antigen positive sera from chronic hepatitis B surface antigen carriers in China
✍ Janet S. Scott; Pei-En Pan; Raymond A. Pace; Theo P. Sloots; Prof. W. Graham Coo 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## Abstract Sera from 20 Chinese patients with chronic hepatitis B were examined for hepatitis B e antigen and hepatitis B virus (HBV) DNA. There was considerable discordance with HBV DNA not being detectable in 10 out of 13 (77%) patients who were hepatitis B e antigen positive. Further testing fo

Quantitative hepatitis B surface antigen
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
✍ Jung Min Lee; Sang Hoon Ahn; Hyon Suk Kim; Hana Park; Hye Young Chang; Do Young 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 2 views

Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utilit